We have previously shown that Smac/DIABLO release from mitochondria appears to be the principal pathway by which TRAIL induces apoptosis of human melanoma. We report that TRAIL-induced release of Smac/DIABLO appears to be downregulated by concomitant signaling through the MEK Erk1/2 kinase pathway and that this inhibits TRAIL-induced apoptosis. Inhibition of Erk1/2 signaling by either the MEK inhibitor U0126 or a dominant-negative mutant of MKK1 markedly sensitized melanoma cells to TRAIL-induced apoptosis. The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126. Caspase-3 activation and cleavage of its substrates, PARP, ICAD and XIAP, were however increased by cotreatment with U0126. This was associated with a rapid reduction in mitochondrial transmembrane potential (MMP) and increased release of Smac/DIABLO into the cytosol. Exploration of events leading to the changes in MMP revealed an increased translocation of Bax from the cytosol to mitochondria in the presence of U0126. There was also a delayed decrease in the levels of expression of Mcl-1. Bcl-2 and Bcl-X L . Over expression of Bcl-2 blocked TRAIL-induced apoptosis in the presence of U0126. Cytochrome c appeared not to play a major role in sensitization of melanoma to TRAIL in that caspase-9 activation was not detected in most of the cell lines. These results suggest that Erk1/2 signaling may protect melanoma cells against TRAILinduced apoptosis by inhibiting the relocation of Bax from the cytosol to mitochondria and that this may reduce TRAIL-mediated release of Smac/DIABLO and induction of apoptosis.
Introduction
TNF-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor (TNF) family that can induce apoptosis in a wide range of cultured malignant cells including melanoma (Wiley et al., 1995; Pitti et al., 1996; Zhang et al., 1999) . The potential significance of TRAIL as an anticancer agent has been supported by studies in animal models showing selective toxicity to human tumor xenografts but not normal tissues (Ashkenazi et al., 1999; Gliniak and Le, 1999; Walczak et al., 1999) . TRAIL-induced apoptotic signaling is believed to be initiated by ligand-induced aggregation of death domains that reside on the cytoplasmic sides of the death receptors, TRAIL-R1 and -R2. This in turn orchestrates the assembly of adapter components such as FADD that activate initiator caspases, caspase-8 and -10, leading eventually to activation of effector caspases such as caspase-3 (Hofmann et al., 1997; .
We have previously shown that TRAIL-induced apoptosis of melanoma is largely dependent on the induction of changes in mitochondrial membrane permeability (MMP) (Thomas et al., 1999) and that release of Smac/DIABLO from mitochondria mediated apoptosis by inhibition of members of the IAP family that were bound to effector caspases . TRAIL induces low levels of Smac/DIABLO release into the cytosol in TRAIL-resistant melanoma cell lines but high levels in TRAIL-sensitive cell lines . The basis for this variation in Smac/DIABLO release is unknown but did not appear to be because of differences in activation of caspase-8 and Bid in that the latter was cleaved to the same extent in both TRAIL-sensitive and -resistant melanoma cell lines . Studies by others have shown that antiapoptotic members of the Bcl-2 family, such as Bcl-2. Bcl-X L and Mcl-1, appear to preserve the integrity of the outer mitochondrial membrane by binding to mitochondrial porin channels Shimizu et al., 1999) . In one model apoptosis proceeds when proapoptotic BH3 only proteins such as Bid, Bim and Noxa bind to the antiapoptotic Bcl-2 members and promote binding of the multidomain proapoptotic Bax and Bak proteins to mitochondria, where they initiate changes in MMP (Shimizu et al., 1999; Cheng et al., 2001; Bouillet and Strasser, 2002) In addition to induction of apoptosis, TRAIL may activate other intracellular signal pathways such as the transcription factor NF-kB Walczak et al., 1997; Franco et al., 2001 ) and members of the mitogen-activated protein kinase (MAPK) family. Among the latter, extracellular signal-regulated kinase 1/2 (Erk1/2) appears to be of particular importance in that it protects cells against apoptosis induced by a variety of stimuli (Cross et al., 2000; Tran et al., 2001) . Erk1/2 lies downstream of a group of kinases including the protein kinase C (PKC), Raf-1, MEK kinase (MKK) and MEK1. On stimulation by extracellular signals, they are successively activated by phosphorylation (Cross et al., 2000; Tran et al., 2001) . The mechanism(s) by which Erk1/2 inhibit apoptosis is not well established. Inhibition of Erk1/2 was shown to enhance the sensitivity of Hela cells to TRAIL-induced apoptosis by actions on events at or above the level of caspase-8 (Tran et al., 2001) , whereas in pancreatic cell carcinoma, downregulation of Bcl-2. Bcl-X L and Mcl-1 was observed (Boucher et al., 2000) .
In the present study, we have examined the relation between TRAIL-induced apoptosis and the Erk1/2 signaling pathway in human melanoma cell lines. We report that TRAIL induces rapid activation of Erk1/2 and that inhibition of Erk1/2 signaling sensitizes melanoma to TRAIL-induced apoptosis. This appeared to be mediated by an increase in TRAIL-induced translocation of Bax from the cytosol to mitochondria and release of Smac/DIABLO from mitochondria into the cytosol. A delayed decrease was observed in the levels of antiapoptotic Bcl-2 family members, in particular, Mcl-1, but the timing of these latter changes suggested they were not the main factor responsible for the increased sensitivity to TRAIL.
Results

TRAIL induces rapid Erk1/2 activation in melanoma cells
We examined in Western blots whether Erk1/2 in melanoma cells was activated by TRAIL using Abs against Erk1/2 and activated (phosphorylated) form of Erk1/2. As shown in Figure 1a , nonactivated Erk1/2 was expressed at equivalent (high) levels in all the melanoma cell lines. Prior to stimulation with TRAIL, the levels of activated Erk1/2 varied between the cell lines with low levels in most of the cell lines and relatively higher levels in Sk-Mel-110, Mel-FH and Mel-RM. After exposure to TRAIL (100 ng/ml) there was strong activation of Erk1/2 that was maximal at 30 min and downregulated thereafter (Figure 1b) . At 2, 4, 8, and 16 h after exposure to TRAIL, the levels of activated Erk1/2 remained stable being slightly higher than the basal levels detected in untreated cells ( Figure  1b and c) . Activation of Erk1/2 by TRAIL was confirmed in a panel of melanoma cell lines as shown in Figure 1d . There was no apparent differences in the extent of TRAIL-induced Erk1/2 activation between TRAIL-sensitive (Mel-RM. Me4405) and -insensitive (IgR3, Mel-RMu. Mel-FH and Mel-LT) melanoma cell lines. Figure 1c shows that TRAIL-induced Erk1/2 activation could be detected even when the concentration of TRAIL was as low as 20 ng/ml and reached a peak when TRAIL was used at 100 ng/ml. As shown in Figure 1e , treatment with z-VAD-fmk did not inhibit TRAIL-mediated activation of Erk1/2. In contrast, Erk1/2 activation was completely blocked by pretreatment with U0126.
Inhibition of Erk1/2 signaling sensitizes melanoma cells to TRAIL-induced apoptosis
We investigated whether activation of Erk1/2 by TRAIL may protect against apoptosis by treating melanoma cells with an MEK-specific inhibitor, U0126. A summary of studies on at least three occasions on a panel of melanoma cell lines and melanocytes is shown in Figure 2a . Treatment with U0126 (20 mm) induced minimal apoptosis in melanocytes and most melanoma cell lines except in SK-Mel-110, Mel-FH and Mel-RM, in which about 10-28% of the cells underwent apoptosis after exposure to U0126. (These were the melanoma cell lines with relatively higher levels of constitutively activated Erk1/2 shown in Figure 1a ). As reported before , melanoma cell lines displayed a wide range of sensitivity to TRAIL-induced apoptosis, and there was an overall correlation between the levels of TRAIL-R2 expression and TRAIL-induced apoptosis (Y ¼ 0+1.36X, R 2 ¼ 0.91, Po0.0001; regression analysis). However, in four cell lines (Mel-FH, IgR3, Mel-RMu and Mel-LT), TRAIL induced low levels of apoptosis despite relatively high levels of TRAIL-R2 expression (Y ¼ 0+2.31X, R 2 ¼ 0.93, P ¼ 0.086). In the presence of U0126, however, TRAIL induced high levels of apoptosis in these lines, which then correlated with
In the presence of U0126, there was a marked increase in TRAILinduced apoptosis in all the cell lines except Mel0538, Me4405 and Mel-CV. The former has been previously shown to lack TRAIL death receptor expression, and the latter are highly sensitive to TRAIL without any additional treatment. These results suggest that activation of Erk1/2 signaling pathway may represent a major intracellular mechanism involved in resistance to TRAIL-induced apoptosis of melanoma cells that express 'normal' levels of TRAIL-R2. Coadministration of TRAIL and U0126 induced apoptosis in about 12% of melanocytes.
To confirm that the observed U0126-mediated sensitization of melanoma to TRAIL-induced apoptosis was because of inhibition of Erk1/2 signaling, we transfected IgR3 and Mel-RMu cells transiently with a dominantnegative mutant of MKK1 (Holmstrom et al., 1999) . While the dominant-negative form of MKK1 by itself did not induce apoptosis among the transfected cell population, it clearly inhibited Erk1/2 activation induced by TRAIL and sensitized the transfected cells to TRAIL-induced apoptosis (Figure 2b and c) . These results confirm that inhibition of Erk1/2 results in increased sensitivity of melanoma cells to TRAILinduced apoptosis.
Sensitization of melanoma to TRAIL-induced apoptosis by inhibition of Erk1/2 occurs downstream of caspase-8 and Bid, but upstream of caspase-3
To examine if sensitization of melanoma to TRAIL by U0126 is dependent on the TRAIL-initiated caspase cascade, we treated IgR3 and Mel-RMu cells with either the pan-caspase inhibitor, z-VAD-fmk, or a caspase-8 specific inhibitor, z-IEDL-fmk, 1 h before adding TRAIL and U0126. Figure 3a shows that both z-VAD-fmk and z-IEDL-fmk inhibited TRAIL-induced apoptosis even in the presence of U0126.
As shown before , exposure to TRAIL alone for 3 h induced cleavage of caspase-8 and Bid in melanoma cell lines. There was no further increase in caspase-8 and Bid cleavage when cells were treated with TRAIL in the presence of U0126 (Figure 3b ). In contrast, the same treatment resulted in a marked increase in caspase-3 activation manifested by increased disappearance of the p32 form of the proenzyme and elevated levels of the p17 form of cleaved caspase-3 (Figure 3c ). Consistent with this, treatment of melanoma cells with TRAIL in the presence of U0126 resulted in a marked increase in cleavage of PARP and ICAD (Figure 3c ). The figures shown are representative of two individual experiments.
Our previous studies have shown that XIAP levels were downregulated in TRAIL-sensitive but not -insensitive melanoma cell lines after exposure to TRAIL . We studied if U0126 pretreatment would result in TRAIL-induced downregulation of XIAP in those insensitive melanoma cell lines, for example, IgR3, Mel-FH, Mel-RMu and Mel-LT. Figure 3d shows that neither U0126 nor TRAIL alone induced significant reduction in XIAP expression levels, but when the agents were combined there was a marked decrease in the percentage of XIAP-positive cells in the cell lines. Downregulation of XIAP expression levels by treatment with TRAIL and U0126 was Sensitization of melanoma to TRAIL-induced apoptosis by inhibition of Erk1/2 is associated with increased release of Smac/DIABLO from mitochondria into the cytosol
The above results suggested that inhibition of Erk1/2 may be acting to increase release of mitochondrial apoptotic proteins. This was examined by measurement of the mitochondrial membrane potential (DCm) in melanoma cells treated with TRAIL in the presence of U0126. Figure 4a and b shows that treatment of melanoma cells with U0126 alone did not cause any changes in the DCm, and that treatment with TRAIL alone for 3 h resulted in a minor reduction in the DCm. However, a marked reduction in the DCm was observed in cells treated with TRAIL for 3 h after exposure to U0126 for 20 h. Addition of U0126 at the same time as TRAIL for 3 h produced similar changes ( Figure 4c ). Reduction in the DCm was detectable as early as 30 min after exposure to TRAIL in the presence of U0126, whereas treatment with TRAIL alone showed no effect on DCm at this time ( Figure 4d ).
The release of Smac/DIABLO and cytochrome c into the cytosol in IgR3 and Mel-RMu cells treated with TRAIL with and without pretreatment with U0126 is shown in Figure 4e . Smac/DIABLO and cytochrome c were localized exclusively in mitochondrial fractions before treatment, but after exposure to TRAIL alone for 3 h. Smac/DIABLO was observed in the cytosolic fractions with a corresponding decrease in the mitochondrial fractions. After treatment with TRAIL in the presence of U0126. Smac/DIABLO was no longer detectable in the mitochondrial fractions, and the levels of expression in the cytosolic fractions were markedly A dominant-negative form of MKK1 inhibited TRAIL-induced activation of Erk1/2 IgR melanoma. Cells were transiently transfected with PMCL HA-tagged MKK1 or with the vector alone. Cells were grown for 48 h after transfection and exposed to 100 ng/ml TRAIL for 30 min. Whole-cell lysates were subjected to Western blot analysis using MAb to activated Erk1/2. (c) A dominant-negative form of MKK1 sensitized IgR3 and Mel-RMu cells to TRAIL-induced apoptosis. Cells were transiently transfected with pMCL HA-tagged MKK1 or with the vector alone (control). Cells were grown for 48 h after transfection and exposed to 100 ng/ml TRAIL for 3 h. Apoptosis measured by annexin V-PE expression on cells gated for green fluorescence emission. The data shown are the representative of two individual experiments Inhibition of TRAIL-induced apoptosis of melanoma by Erk 1/2 signaling XD Zhang et al increased. Similar but less marked changes were observed in cytochrome c levels.
The specificity of these effects for Erk1/2 was examined in Mel-IgR3 cells that were transfected with the dominant-negative MKK1. As shown in Figure 4f , Smac/DIABLO was released from mitochondria into the cytosol to a greater extent in melanoma cells transfected with the DN MKK1 compared to cells transfected with the vector alone.
We tested if increased release of Smac/DIABLO and cytochrome c may promote caspase-9 activation. Caspase-9 cleavage was not detected in all the melanoma cell lines except that a small amount of the p37 fragment was observed in Mel-RM and Mel-RMu after treatment with TRAIL in the presence of U0126 (Figure 4g ). Consistent with this, a specific inhibitor for caspase-9, z-LEHD-fmk, when used at concentrations known to block caspase 9 activity (Ozoren et al., 2000) had a negligible effect on TRAIL-induced apoptosis irrespective of whether U0126 was coadministered ( Figure 4h ).
Taken together, these results suggest that Erk1/2 signaling protects melanoma cells from TRAILinduced apoptosis by inhibiting changes in MMP and release of Smac/DIABLO from mitochondria into the cytosol.
Overexpression of Bcl-2 inhibits the effects of U0126 on TRAIL-induced apoptosis
To confirm the role of changes in MMP in sensitization of melanoma cells to TRAIL-induced apoptosis by inhibition of Erk1/2, we transfected cDNA encoding Bcl-2 into Mel-RM and Mel-FH cells. Bcl-2 expression was measured with a MAb specific to Bcl-2 in permeabilized cells by flow cytometry. There was an increase in the levels of Bcl-2 in the Bcl-2-transfected cells, but the levels in the cells transfected with the vector alone were similar to those in the parental cells (data not shown). Figure 5a shows that the levels of TRAIL-induced apoptosis in Bcl-2-transfected cells in the presence or absence of Figure 5C illustrates that the TRAIL-induced release of Smac/DIABLO and cytochrome c from mitochondria in the presence of U0126 was nearly completely blocked in Bcl-2 transfectants.
Inhibition of Erk1/2 downregulates the expression levels of Mcl-1, Bcl-2 and Bcl-X L in melanoma cells
The constitutive expression levels of Bcl-2 homologs, Bcl-2, Bcl-X L. Mcl-1, A1, Bax and Bad is shown in Figure 6a . There was no correlation between the levels of Bcl-2 or Bcl-X L expression and the sensitivity to TRAIL-induced apoptosis in that lower levels of expression were frequently observed in resistant lines, for example, IgR3, Mel-RMu, Mel-FH and Mel-LT, whereas higher levels were seen in sensitive lines, for example, Mel-RM and Me4405. However, Mcl-1 expression levels appeared to correlate more closely with the sensitivity of melanoma cells to TRAIL. The TRAIL-resistant lines (IgR3, Mel-RMu, Mel-FH and Mel-LT) generally expressed higher levels and the sensitive lines (Mel-RM and Me4405) lower levels of this protein. The proapoptotic Bcl-2 homologs, Bax and Bad, were equivalently expressed by the melanoma cell lines irrespective of their sensitivity to TRAIL. There was no or only low levels of A1 in the melanoma cells. We next examined whether U0126 may affect the expression of Bcl-2 homologs in melanoma cells. After 20 h treatment with U0126, Mcl-1 protein expression levels were markedly decreased in all the melanoma cell lines by 40-72%. Bcl-2 and Bcl-X L expression levels were decreased by 10-26% and 15-33%, respectively (Figure 6b ). In contrast, the expression levels of Bax and Bad remained unchanged before and after U0126 treatment (data not shown). The kinetics of downregulation of Mcl-1 after exposure to U0126 in IgR3 cells is shown in Figure 6c . There was a slight decrease in the levels of expression of Mcl-1 at 8 h after U0126 addition. By 16 h, the levels of expression were close to those seen at 20 h after U0126 treatment. There was no correlation between the extent of downregulation of Mcl-1, Bcl-2 or Bcl-X L and the degree of sensitization of melanoma to TRAIL-induced apoptosis by U0126 (data not shown). The results shown are representative of two individual experiments.
Mcl-1 mRNA expression levels in melanoma cells were quantitated by real-time RT-PCR before and after exposure of cells to U0126. Figure 6d shows that the levels of Mcl-1 mRNA expression in IgR3 and MelRMu cells were decreased at 20 h after treatment with U0126 and downregulation of Mcl-1 mRNA was observed as early as 4 h after exposure to U0126 (Figure 6e ).
Inhibition of Erk1/2 activation promotes translocation of Bax from the cytosol to mitochondria
It was reported that translocation of Bax from the cytosol to mitochondria plays a key role in TRAIL-induced changes of mitochondria (Burn and el-Deiry, 2001; Deng et al., 2001) . We examined whether the ERK1/2 pathway may play a role in regulation of the location of Bax. As shown in Figure 7a , the Bax protein was exclusively Inhibition of TRAIL-induced apoptosis of melanoma by Erk 1/2 signaling XD Zhang et al located in the cytosol before treatment and was partially redistributed to mitochondria after exposure to TRAIL. The proportion of Bax that was redistributed to mitochondria after exposure to TRAIL was much higher in the TRAIL-sensitive cell line Mel-RM than the insensitive cell line IgR3 (61% vs 29%). U0126 treatment alone did not result in significant translocation of Bax; however, after treatment with U0126 and TRAIL, there was a marked increase in relocation of Bax to mitochondria in the cell lines, particularly in the resistant IgR3 line. In all, 93% of Bax in IgR3 and 75% in Mel-RM were detected in the mitochondrial fractions. Figure 7a also shows that overexpression of Bcl-2 did not inhibit translocation of Bax from the cytosol to mitochondria but increased the localization, particularly after exposure to TRAIL and U0126. Similar results were obtained in a repeat of the experiment. We studied by flow cytometry, the conformation status of Bax in IgR3 and Mel-RM cells before and after exposure to TRAIL in the presence or absence of U0126 by using an antibody (NT) directed against the NH 2 -terminal region of Bax (Bellosillo et al., 2002; Haefen et al., 2002) . (This region is occluded in intact cells and is not available for binding by Bax-NH 2 -terminal epitopespecific antibodies. Bax translocation involves a conformation change that exposes the NH 2 -terminus and the hydrophyobic COOH-terminus that targets mitochondria (Desagher et al., 1999; Hsu et al., 1998) .) As shown in Figure 7b , before treatment there was weak positivity of cells to this antibody recorded as mean fluorescent intensity (MFI). TRAIL at 1 h induced a marked increase in MFI in Mel-RM cells, and to a lesser extent in IgR3 cells. (The value of MFI increased from 2.95 to 5.97 in Mel-RM, and from 2.8 to 3.9 in IgR3.) In the presence of U0126, TRAIL induced a further increase in MFI in Mel-RM cells (7.17) and a marked increase in IgR3 cells (MFI ¼ 7.59). These changes in MFI were consistent with levels of apoptosis induced by TRAIL with and without the inhibitor of Erk1/2.
Another candidate for induction of changes in MMP following inhibition of Erk1/2 activation is Bad. Activated Erk1/2 can phosphorylate Bad at its serine 112 residue resulting in the inactive form of phosphorylated Bad that is sequestered in the cytosol bound to 14-3-3 protein, thus freeing Bcl-X L and Bcl-2 to promote cell survival (Zha et al., 1996; Scheid and Duronio, 1998) . We tested whether Bad may be phosphorylated by activated Erk1/2 induced by TRAIL using an Ab that specifically recognizes Bad phosphorylated at serine 112. As shown in Figure 7c , low levels of serine 112-phosphorylated Bad were detected in all the melanoma cell lines prior to treatment. There was no further increase in the expression levels at 0.5, 1, 2 and 3 h after exposure to TRAIL with or without pretreatment with U0126. (20mm), TRAIL (100 ng/ml) or the combination of both for 3 h were subject to flow cytometry analysis using an antibody directed against the NH 2 -terminal region of Bax. MFI was shown as the ratio of geometric mean fluorescence intensity of the test sample and the corresponding isotype control. The data shown are the mean+s.e. of three individual experiments. (c) TRAIL did not induce phosphorylation of Bad at Ser 112 site. IgR3 and Mel-RMu cells were treated with TRAIL (100 ng/ml) for indicated time periods and whole-cell lysates were subjected to Western blot analysis
Discussion
We have previously shown that there is a large variation in response of different melanoma cell lines to apoptosis induced by TRAIL. This was accounted for in part by variation in TRAIL death receptor expression but was still evident even when comparisons were made between melanoma lines with similar levels of death receptor expression . We found that this variation appeared to be accounted for by different levels of Smac/DIABLO release from mitochondria following exposure of the melanoma cells to TRAIL . In the present study we show that TRAIL induces activation of Erk1/2 kinases. Moreover, we show that melanoma cells having normal levels of TRAIL death receptors but low TRAILinduced apoptosis became sensitive to TRAIL in the presence of inhibitors of this pathway.
Activation of Erk1/2 in melanoma cells by TRAIL is consistent with previous studies showing that TRAIL (like TNF-a and Fas-L) induced rapid Erk1/2 activation in Hela cells . The signaling pathway involved in activation of Erk1/2 by TRAIL is not clear, but the present study suggests it is independent of the caspase pathway as activation was not blocked by a pan caspase inhibitor. It was maximal at 30 min after exposure to TRAIL. Erk1/2 activation was not seen in cells without TRAIL death receptors. Several members of the MAPK kinase family (NIK and MEKK1), which are upstream of the Erk1/2 signalling pathway, were reported to be involved in activation of NF-kB by TRAIL (Lee et al., 1997; Dhawan and Richmond, 2002) . It is therefore possible that the same signaling pathway is involved in TRAIL-induced activation of Erk1/2. Further studies are needed to answer this question.
Inhibition of the Erk1/2 pathway by itself can induce apoptosis in some malignant cell lines, such as those from acute myeloid leukemia and pancreatic cancer (Boucher et al., 2000; Dai et al., 2001; Milella et al., 2001) . However, inhibition of Erk1/2 by itself did not induce apoptosis of the melanoma lines except for low levels in three of the lines that had low levels of constitutively activated Erk1/2. This suggests that constitutive activation of Erk1/2 kinases is not needed for survival of these melanoma lines and only becomes important for survival of cells when activated by exogenous stimuli, such as TRAIL.
Inhibition of the Erk1/2 pathway with the MEK inhibitor U0126 or with a dominant negative MKK1 resulted in a marked increase in sensitivity of melanoma cells to TRAIL-induced apoptosis. This increase was most evident in melanoma cells that had low sensitivity to TRAIL despite normal levels of death receptor expression. In the presence of the inhibitor of Erk1/2, the sensitivity of the cell lines to TRAIL appeared consistent with their level of death receptor expression. This suggests that the Erk1/2 pathway was responsible for the resistance of these cell lines to TRAIL. Cell lines with high death receptor expression and high sensitivity to TRAIL had little or no increase when treated with U0126.
To identify the antiapoptotic mechanisms associated with activation of Erk1/2, we examined key targets in the apoptotic pathway induced by TRAIL in the presence and absence of the MEK inhibitor UO126. These studies found no evidence for increased activation of caspase 8 or Bid, but clearly showed an increase in activation of caspase 3 in cells treated with the inhibitor. This was associated with an early and more marked increase in MMP induced by TRAIL and release of Smac/DIABLO. We have shown previously that inhibition of the IAP family members by Smac/DIABLO appears to be the main pathway to apoptosis induced by TRAIL in melanoma cells ). This may reflect in part the absence of Apaf-1 in most melanoma, as reported by others (Soengas et al., 2001) . In the present studies, caspase 9 cleavage was barely detectable and apoptosis was not inhibited by an inhibitor of caspase 9. This supports evidence from our previous studies that the release of Smac/DIABLO is the main pathway to apoptosis in melanoma cells rather than activation of caspase 9 by formation of apoptosomes.
These results suggested that activation of Erk1/2 was protecting against apoptosis at the level of the mitochondria. Members of the Bcl-2 family are believed to be responsible for protecting against such changes perhaps by binding to proapoptotic BH3 only members, such as Bid, Bim and Noxa (O'Connor et al., 1998; Korsmeyer et al., 2000; Oda et al., 2000; Cheng et al., 2001; Puthalakath and Strasser, 2002) . Involvement of the Bcl-2 family was supported by studies showing that overexpression of Bcl-2 prevented the increase in apoptosis induced by the MEK inhibitor. The family member A1 was barely detectable in the melanoma cell lines, but constitutive Mcl-1 levels appeared to show an inverse correlation with apoptosis induced by TRAIL.
Treatment of melanoma cells with the MEK inhibitor was associated with downregulation of Bcl-2, Bcl-X L and particularly Mcl-1. However, comparison of the kinetics of Erk1/2 activation by TRAIL and downregulation of the antiapoptotic Bcl-2 family members following treatment with U0126 made it unlikely that changes in the latter were responsible for the observed effects of the inhibitor on changes in MMP. This is because increases in MMP were seen as early as 30 min after exposure to both TRAIL and U0126, whereas decreased levels of the Bcl-2 protein family were not detected until approximately 16 h after treatment with the inhibitor. The more likely explanation appears to be the observed relocation of the multidomain BH3 proapoptotic protein. Bax, from the cytosol to the mitochondria. Studies by others have suggested that relocation of Bax from the cytosol to mitochondria is a key event in induction of apoptosis by TRAIL (Burn and el-Deiry, 2001; Deng et al., 2001) . In view of this, we examined the conformation status and distribution of Bax before and after TRAIL and with or without pretreatment with the MEK inhibitor. These studies showed a rapid conformation change and relocation of Bax to mitochondria following exposure to TRAIL, which was more evident in TRAIL-sensitive compared to TRAIL-resistant melanoma lines and more evident in the presence of TRAIL plus the MEK inhibitor U0126. The latter suggests that Erk1/2 kinase activity is responsible for maintenance of Bax in the cytosol and inhibition of this activity allows Bax to oligomerize in the mitochondrial membrane. Support for the importance of the phosphorylation status in Bax translocation comes from studies showing that phosphatase inhibitors may prevent relocation of Bax to mitochondria and inhibit apoptosis (Ganju and Eastman, 2002) . Further studies are needed to confirm the importance of Bax relocation in sensitization of melanoma cells to TRAIL by inhibitors of the Erk1/2 pathway and the substrates involved.
These results nevertheless provide support for the possible use of Erk1/2 inhibitors to increase the effectiveness of TRAIL or effector mechanisms dependent on TRAIL in treatment of melanoma. This combination did not have significant toxicity against melanocytes but a wider range of normal tissues need to be tested. In addition, further studies are needed to examine whether the combination is effective against fresh isolates of melanoma and human xenografts in vivo. We are also unable to say whether Erk1/2 inhibitors would sensitize melanoma cells to apoptosis induced by stimuli other than TRAIL, such as chemotherapeutic agents. Erk1/2 was not constitutively active in most of the melanoma lines and the Erk1/2 inhibitors would be expected to sensitize cells only if the apoptotic stimulus also activated Erk1/2.
Materials and methods
Cell lines
Human melanoma cell lines, Mel0538, Me4405, IgR3, Mel-FH, Mel-RMu, Mel-RM, Mel-CV, Mel-LT, MM200 and Sk-Mel-28, have been described previously . SkMel-110 was a kind gift from Dr A Albino (American Health Foundation, Valhalla, NY, USA). The cell lines were cultured in DMEM containing 5% FCS (Commonwealth Serum Laboratories, Melbourne, Australia). Melanocytes were kindly provided by Dr P Parson (Queesland Institute of Medical Research, Brisbane, Australia) and cultured in medium supplied by Clonetics (Edward Kellar, Vic., Australia).
Antibodies, recombinant proteins and other reagents
Recombinant human TRAIL (lot 6321-19) was supplied by Immunex (Seattle, WA, USA). The preparation was supplied as a leucine zipper fusion protein, which required no further cross linking for maximal activity. The MAbs against TRAIL-R1 (IgG2a hu TR1-M271; lot 7136-07) and TRAIL-R2 (IgG1 hu TR2-M413; lot 5274-96) were supplied by Immunex and have been described previously. The rabbit antiserum against ICAD (Daffine) and the control preimmune serum were a kind gift from Dr SL Sabol (National Cancer Institute. Bethesda. MD, USA) and were described elsewhere (Sabol et al., 1998) . The rabbit polyclonal Abs against caspase-3, caspase-8 and Bid and the mouse MAbs against cytochrome c and PARP were from Pharmingen (Bioclone, Marrickville, Australia). Rabbit polyclonal Abs against c-IAP1, c-IAP2 and A1, and mouse MAbs against Bcl-2, Bcl-X L and Mcl-1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The mouse MAb against phosphorylated Erk1/2 was also purchased from Santa Cruz Biotechnology. The mouse polyclonal Ab against Bax was supplied by Oncogene Research Products (Cambridge. MA, USA). The mouse MAb against XIAP was purchased from Transduction Laboratories (Lexington, KY, USA). The rabbit polyclonal Ab against Smac was a kind gift from Dr Xiao Dong Wang (Howard Hughes Medical Institute, Dallas, TX, USA). The rabbit polyclonal Ab against cleaved caspase-9 was purchased from New England Biolabs (Beverly, MA, USA). Rabbit polyclonal Ab against Erk1/2 and the MEK inhibitor, U0126, were purchased from Promega Corporation (Madison, WI, USA). Rabbit polyclonal antiBax against amino acids 1-20 was purchased from Upstate Biotechnology (Lake Placid, NY, USA). The MAb against cytochrome c oxidase subunit 4 (COX IV) was purchased from Molecular Probes (Eugene, OR, USA), Catal. No. 6401. Isotype control Abs used were the ID4.5 (mouse IgG2a) MAb against Salmonella typhi supplied by Dr L Ashman (Institute for Medical and Veterinary Science, Adelaide, Australia), the 107.3 mouse IgG1 MAb purchased from PharMingen (San Diego, CA, USA) and rabbit IgG from Sigma Chemical Co. (Castle Hill, Australia). The general caspase inhibitor, Z-ValAla-Asp (Ome)-CH 2 F (z-VAD-fmk), the caspase-8 inhibitor, Z-lie-Glu(Ome)-Thr-Asp(Ome)-CH 2 F (z-IETD-fmk), and the caspase-9 inhibitor. Z-Leu-Glu(Ome)-His-Asp(Ome)-CH2F (z-LEHD-fmk), were purchased from Calbiochem (La Jolla, CA, USA).
Plasmid vector and transfection
The expression construct of pEF Bcl-2 was a kind gift from Dr David Vaux (The Walter and Eliza Hall Institute of Medical Research), which was transfected into melanoma cells and the resulting transfectants were maintained as described previously (Franco et al., 2001; Zhang et al., 2001) . The pMCL-HA-MKK1-8E (K97) dominant-negative construct of the MAPK kinase is described elsewhere (Holmstrom et al., 1999) . It was transiently transfected into melanoma cells by electroporation, as described elsewhere (Franco et al., 2001 ).
Flow cytometry
Immunostaining on intact and permeabilized cells was carried out as described previously . Analysis was carried out using a Becton Dickinson (Mountain View, CA, USA) FACScan flow cytometer. The percentage of antigenpositive cells was calculated as the difference in positive area between the positive and negative control histograms. The positive area was that to the right of the intersection of the two curves .
Apoptosis
Apoptotic cells were determined by the propidium iodide method described elsewhere .
Mitochondrial membrane potential (DCm)
Methods used were similar to those described previously (Thomas et al., 1999) . Tumor cells were cultured in 24-well plates and allowed to reach exponential growth for 24 h before treatment. Mitotracker red CMXRos (Molecular probes. Eugene. OR, USA) was added at 100 nm during the last 30 min of treatment. The medium was removed into a 75-mm Falcon polystyrene tube and the adherent cells were trypsinized and collected into the same tube. After washing with PBS, the cells were analysed using a FACScan flow cytometer (Becton Dickinson. Sunnyvale, CA, USA) for mitotracker uptake. Untreated cells were used as controls.
Western blot analysis
Methods used were as described previously , with minor modification. Briefly, the protein content of cell extracts was determined by the Bradford assay (Bio-Rad). A total of 20-30 mg protein was electrophoresed on 10-15% SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were blocked, incubated with primary Abs at the appropriate concentration, and subsequently incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (1 : 3000 dilution, respectively; Bio-Rad). Labeled bands were detected by Renaissance Western Blot Chemiluminescence Reagent (New England Nuclear Life Science Products, Boston, MA, USA) and exposed on Hyper MP autoradiography film (Amersham). The density of the bands was quantitated on a Macintosh computer using the public domain NIH image program, which is available on the internet (http://rsb.info.nih.gov/nih-image). Whole-cell extracts were obtained by lysing cells in a Triton X-100-based lysis buffer (10% Triton X-100, 10% glycerol, 150 mm NaCl, 20mm Tris (pH 7.5), and protease inhibitor cocktail tablets used as per the manufacture's instruction (Roche Diagnostics; Mannheim, Germany)).
Preparation of mitochondrial and cytosolic fractions
Methods used for subcellular fraction were similar to the methods described by others (Liu et al., 1996) . Adherent cells were removed by trypsinization in 0.25% trypsin at 371C for 5 min. When cells were pretreated with reagents, floating cells were also collected in the same tubes. After being washed once with ice-cold PBS, the cell pellet was suspended in five volumes of buffer A (20 mm HEPES-KOH (pH 7.5), 10 mm KCI, 1 mm Na-EGTA, 1 mm DTT and 0.1 mm phenylmethylsulfonyl fluoride containing 250 mm sucrose) supplemented with protease inhibitor cocktail tablets (one tablet in 10 ml). After incubation on ice for 15 min, the cells were disrupted by passing them 15 times through a 22-gauge needle. After centrifugation twice at 750 g for 10 min at 41C, the supernatant was collected and centrifuged at 10 000 g for 15 min at 41C, and the resulting mitochondrial pellets were resuspended in buffer A. The supernatants of the 10 000 spin were further centrifuged at 100 000 g for 1 h at 41C, and the resulting supernatants were designated as the S-100 cytosolic fraction.
Real-time PCR
Total RNA was isolated with SV total RNA isolation system (Promega). Reverse transcription PCR was carried out using MMLV transcriptase and Oligo d(T) and the resulting cDNA products were used as template for real-time PCR assays. Real-time RT-PCR was performed using the ABI Prism 7700 sequence detection system (PE Applied Biosystems). A volume of 25 ml of mixture was used for reaction, which contains 5 ml cDNA sample (0.5-1 mg/ml), 300 nm Mcl-1 forward primer (GGAAGGCCTGGAGACCTTA), 300 nm Mcl-1 reverse primer (CAACGATTTCACATCGTCTTCGT), 200 nm Mcl-1 probe (VIC-TTGATGTCCAGTTTCCGAAGCATGCCT-TAMRA) and 9 mm MgCl 2 . The probe was designed to cross the boundary of intron and exon of Mcl-1 cDNA. Analysis of cDNA for b-actin was included as a control. After incubation at 501C for 2 min followed by at 951C for 10 min. the reaction was carried out for 40 cycles as the following: 951C for 15 s and 601C for 1 min. The threshold cycle value (C t ) was normalized against b-actin cycle numbers. The relative abundance of mRNA expression of a control sample was arbitrarily designated as 1, and the values of the relative abundance of mRNA of other samples was calculated accordingly.
